Previous 10 | Next 10 |
TORONTO, ON / ACCESSWIRE / November 6, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to present at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020 at 12:...
Edesa Biotech (EDSA) has completed enrollment of more than 50% of the patients planned for the first cohort of a Phase 2b study evaluating its lead product candidate, EB01 cream as a monotherapy for chronic allergic contact dermatitis.The 46-subject study is evaluating the safety and eff...
TORONTO, ON / ACCESSWIRE / November 3, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment of more than 50% of the patients planned for the first cohort of a Phase 2b clinical study evaluating the company's dr...
Edesa Biotech ([[EDSA]] +3.1%), receives FDA clearance to begin the Phase 2 portion of its Phase 2/3 clinical study of its investigational drug, EB05, for treatment of Covid-19.EB05 is an experimental monoclonal antibody that the company believes could regulate the overactive immune response ...
TORONTO, ON / ACCESSWIRE / October 19, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received clearance from the U.S. Food and Drug Administration (FDA) to begin the Phase 2 portion of its Phase 2/3 clinical study of its investigational drug, EB05,...
Edesa Biotech (NASDAQ: EDSA ) is up 5.56% pre-market following disclosure that CEO Pardeep Nijhawan increases its stake to 34.4% in the company. More news on: Edesa Biotech, Inc., Stocks on the move, Healthcare stocks news, Read more ...
MARKHAM, ON / ACCESSWIRE / September 18, 2020 / Dr. Pardeep Nijhawan ("Dr. Nijhawan") announces that his beneficial ownership of common shares (" Common Shares ") in the capital of Edesa Biotech, Inc. (" Edesa ") has increased by more than 2% of the issued and outstanding Common Shares from ...
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...
Edesa Biotech (NASDAQ: EDSA ) : Q3 GAAP EPS of -$0.20 misses by $0.02 . Revenue of $0.11M beats by $0.06M . Press Release More news on: Edesa Biotech, Inc., Earnings news and commentary, Healthcare stocks news, ,
TORONTO, ON / ACCESSWIRE / August 12, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and nine months ended June 30, 2020 and provided an update on its business. During the quarter, Edesa received Canadian ...
News, Short Squeeze, Breakout and More Instantly...
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS. Paridipru...
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provid...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...